Therefore, knowing a company's potential revenue growth is crucial. For Merck, the consensus sales estimate for the current quarter of $15.52 billion indicates a year-over-year change of +6.1%.

Shares of this pharmaceutical company have returned +1.2% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Large Cap Pharmaceuticals industry, to which Merck ...

Merck & Co’s Keytruda cancer immunotherapy is set to become the world’s top-selling drug by annual revenue in 2023, smashing sales records set by AbbVie’s ageing inflammatory disease drug ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...

shares of this pharmaceutical company have returned -1.9%, compared to the Zacks S&P 500 composite's -2.4% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Merck ...